Anglo-Swedish drugmaker AstraZeneca said on Tuesday it will acquire biotechnology firm TeneoTwo in a deal worth up to $1.27 billion (€1.22 billion), in a move to bolster its blood cancer portfolio.
The deal includes the US-based company’s experimental treatment for a type of non-Hodgkin lymphoma, AstraZeneca said in a statement.
The experimental therapy, a T-cell engager, is a part of the immunotherapy class of treatments that use the body's own defence mechanism to fight cancerous cells.
AstraZeneca said it has agreed to buy all outstanding equity of TeneoTwo for an upfront payment of $100 million on deal close, and additional milestone-related payments of up to $1.17 billion.
‘I joke that my two children are my retirement plan, but I’m not sure they see it that way’
Ireland has chance to take a leading AI regulatory role – starting with the appointment of a dedicated minister
High rental costs mean Dublin ranks in top 10 most expensive cities in Europe
Is a room rented under rent-a-room scheme restricted by RPZ rules?
The transaction is likely to close in the third quarter of this year and not expected to impact AstraZeneca's 2022 outlook, the London-listed company said.
TeneoTwo was spun-off from Teneobio, which was bought by US biotechnology company Amgen last year. - Reuters
(c) Copyright Thomson Reuters 2022
